Skin in the game.

Headline: Koinonia? Please. Try cemiplimab. Fine, we’ll use it in a sentence. Cemiplimab is a potent monoclonal antibody to PD-1. In this phase 1 trial, cemiplimab was given to patients with advanced or metastatic cutaneous squamous cell carcinoma (cSCC). If you think about it, there’s good rationale here because cSCC is often hypermutated and is commonly seen among immunosuppressed individuals. In line with this hypothesis, the response rate was close to 50% and most responders maintained durable response with minor toxicity. And, keep in mind, patients weren’t selected based on PD-1 expression. Bottom Line: The PD-1 inhibitor cemiplimab is active in advanced cSCC. | Migden, N Engl J Med 2018